Image may be NSFW.
Clik here to view.
Shares in Intersect ENT (NSDQ:XENT) held steady today after the medical device maker topped expectations on Wall Street with its first-quarter results.
The Menlo Park, Calif.-based company posted a net loss of -$6.1 million, or -21¢ per share, on sales of $24.7 million for the 3 months ended March 31, for bottom-line growth of 8.8% on sales growth of 20.8% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT beats The Street with Q1 sales, earnings appeared first on MassDevice.
